Changes in the Ganglion Cell-inner Plexiform Layer after Consecutive Intravitreal Injections of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the effect of intravitreal anti-vascular endothelial growth factor (VEGF) injections onganglion cell-inner plexiform layer (GCIPL) thickness in patients with age-related macular degeneration (AMD). Methods: This retrospective study included patients with continuous anti-VEGF treatment who were administeredat least three consecutive injections for unilateral neovascular AMD. The GCIPL thickness of the studyeyes was compared before and after treatment and with healthy fellow eyes using spectral-domain opticalcoherence tomography. We also evaluated best-corrected visual acuity, age, and intraocular pressure. Results: In total, 96 eyes of 48 patients (14 females and 34 males; mean ± standard deviation [SD] age, 70.10 ±8.89 years) with mean number of 6.29 (SD ± 3.76) anti-VEGF injections and a mean follow-up period of 24.93months (SD ± 19.86) were included in the study. After three consecutive intravitreal injections of anti-VEGF, themean GCIPL thickness was significantly reduced from 70.50 (SD ± 14.06) to 65.97 (SD ± 13.91) μm. Borderlineor nonsignificant decrease was also observed in GCIPL thickness for each sector. At the end of the study, themean GCIPL thickness was further reduced to 62.56 (SD ± 16.30) μm, and significant decreases were alsoobserved in all other sectors compared with baseline. Conclusions: It has been observed that GCIPL thickness can decrease with only three consecutive anti-VEGFinjections as well as with long-term treatment in AMD patients.
Abstract
Purpose: To investigate the effect of intravitreal anti-vascular endothelial growth factor (VEGF) injections onganglion cell-inner plexiform layer (GCIPL) thickness in patients with age-related macular degeneration (AMD). Methods: This retrospective study included patients with continuous anti-VEGF treatment who were administeredat least three consecutive injections for unilateral neovascular AMD. The GCIPL thickness of the studyeyes was compared before and after treatment and with healthy fellow eyes using spectral-domain opticalcoherence tomography. We also evaluated best-corrected visual acuity, age, and intraocular pressure. Results: In total, 96 eyes of 48 patients (14 females and 34 males; mean ± standard deviation [SD] age, 70.10 ±8.89 years) with mean number of 6.29 (SD ± 3.76) anti-VEGF injections and a mean follow-up period of 24.93months (SD ± 19.86) were included in the study. After three consecutive intravitreal injections of anti-VEGF, themean GCIPL thickness was significantly reduced from 70.50 (SD ± 14.06) to 65.97 (SD ± 13.91) μm. Borderlineor nonsignificant decrease was also observed in GCIPL thickness for each sector. At the end of the study, themean GCIPL thickness was further reduced to 62.56 (SD ± 16.30) μm, and significant decreases were alsoobserved in all other sectors compared with baseline. Conclusions: It has been observed that GCIPL thickness can decrease with only three consecutive anti-VEGFinjections as well as with long-term treatment in AMD patients.
참고문헌 (28)
- Sobrin L, "Nature and nurture-genes and environment-predict onset and progression of macular degeneration", Prog Retin Eye Res, 40, pp.1~15 (2014)
- Bird AC, "An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group", Surv Ophthalmol, 39, pp.367~374 (1995)
- Ferris FL 3rd, "Age-related macular degeneration and blindness due to neovascular maculopathy", Arch Ophthalmol, 102, pp.1640~1642 (1984)
- Bressler NM, "Age-related macular degeneration", Surv Ophthalmol, 32, pp.375~413 (1988)
- Ambati J, "Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies", Surv Ophthalmol, 48, pp.257~293 (2003)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration : two-year results", Ophthalmology, 119, pp.1388~1398 (2012)
- Blaauwgeers HG, "Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation", Am J Pathol, 155, pp.421~428 (1999)
- Marneros AG, "Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function", Am J Pathol, 167, pp.1451~1459 (2005)
- Nishijima K, "Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury", Am J Pathol, 171, pp.53~67 (2007)
- Cho HJ, "Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation", Am J Ophthalmol, 159, pp.285~292 (2015)
- Zinkernagel MS, "Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant", Invest Ophthalmol Vis Sci, 56, pp.1894~1900 (2015)
- Foxton RH, "VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma", Am J Pathol, 182, pp.1379~1390 (2013)
- 이지민, "Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells", Korean Journal of Ophthalmology, 31(4), pp.360~365 (2017), 대한안과학회
- Zucchiatti I, "Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration", Am J Ophthalmol, 160, pp.602~607 (2015)
- Brar VS, "Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells", Mol Vis, 16, pp.1848~1853 (2010)
- Cheng CK, "Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection", Retina, 29, pp.306~312 (2009)
- Horsley MB, "Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy", Am J Ophthalmol, 150, pp.558~561 (2010)
- Entezari M, "Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration", J Ophthalmic Vis Res, 9, pp.449~452 (2014)
- Shin HJ, "Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor", Invest Ophthalmol Vis Sci, 55, pp.2403~2411 (2014)
- Shin HY, "Comparative study of macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer measurement : structure-function analysis", Invest Ophthalmol Vis Sci, 54, pp.7344~7353 (2013)
- Ohkubo S, "Focal relationship between structure and function within the central 10 degrees in glaucoma", Invest Ophthalmol Vis Sci, 55, pp.5269~5277 (2014)
- Beck M, "Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration", Am J Ophthalmol, 167, pp.10~17 (2016)
- Lee HJ, "Ganglion cell-inner plexiform layer thickness in retinal diseases : repeatability study of spectral-domain optical coherence tomography", Am J Ophthalmol, 160, pp.283~289 (2015)
- Alshareef RA, "Segmentation errors in macular ganglion cell analysis as determined by optical coherence tomography in eyes with macular pathology", Int J Retina Vitreous, 3, pp.25~ (2017)
- 김형준, "스펙트럼 도메인 빛간섭단층촬영에서 발생하는 오류", 대한안과학회지, 52(8), pp.943~951 (2011), 대한안과학회
- Ho J, "Assessment of artifacts and reproducibility across spectral-and time-domain optical coherence tomography devices", Ophthalmology, 116, pp.1960~1970 (2009)
- Patel PJ, "Segmentation error in Stratus optical coherence tomography for neovascular age-related macular degeneration", Invest Ophthalmol Vis Sci, 50, pp.399~404 (2009)